TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Interaction Details
01. General Information
Pair Name Resveratrol, Olaparib
Phytochemical Name Resveratrol (PubChem CID: 445154 )
Anticancer drug Name Olaparib (PubChem CID: 23725625 )
Structure of
Phytochemical
2D-img
Download
2D MOL 3D MOL
Structure of
Anticancer Drug
2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 379
Pair Name Resveratrol, Olaparib
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Induction-->DNA damage
Gene Regulation Up-regulation Expression BAX hsa581
Down-regulation Expression BCL-xL hsa598
Down-regulation Expression BRCA1 hsa672
Down-regulation Expression PARP1 hsa142
In Vitro Model MCF-7 Invasive breast carcinoma of no special type Homo sapiens (Human) CVCL_0031
T-47D Invasive breast carcinoma of no special type Homo sapiens (Human) CVCL_0553
In Vivo Model Tumor was induced by injecting MCF-7 cells (1 × 107 in 200 μL sterile 1X PBS) on the right breast fat pads of 6–7 weeks old female BALB/c mice. After formation of tumor, the mice were orally treated with RES + OLA combination (40 mg/kg RES and 20 nM/kg OLA per day) for 30 days.
Result RES + OLA combination treatment enhanced breast cancer cell death by causing excessive DNA damage and also simultaneously inhibiting the HR pathway.
03. Reference
No. Title Href
1 Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway. Exp Cell Res. 2022 Nov 1;420(1):113338. doi: 10.1016/j.yexcr.2022.113338. Click
It has been 47156 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP